Journal of Indira Gandhi Institute Of Medical Sciences

REVIEW ARTICLE
Year
: 2021  |  Volume : 7  |  Issue : 1  |  Page : 2--5

Management of dyslipidemia in chronic kidney disease


Prit Pal Singh, Amresh Krishna, Om Kumar 
 Department of Nephrology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India

Correspondence Address:
Prit Pal Singh
Room No: 14, Department of Nephrology, Old Administrative Block, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna - 800 014, Bihar
India

Dyslipidemia is one of the most important modifiable risk factors for cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. Lipid profile in CKD differs from that in general population. Even at normal or near-normal lipid levels, subparticles are more atherogenic and more pro-inflammatory. Because of altered clearance and metabolism of various lipid-lowering agents in CKD, its safety on long-term use remains a serious concern. Statins and ezetimibe remain drug of choice for most of the patients. The lowest and the safest dose of the drugs is guided by various trials. Until recently, not much study was available to formulate a guideline for these patients. However, recent studies and meta-analysis have solved this problem to some extent and that's evident with latest guidelines published by KDIGO and ACC/AHA.


How to cite this article:
Singh PP, Krishna A, Kumar O. Management of dyslipidemia in chronic kidney disease.J Indira Gandhi Inst Med Sci 2021;7:2-5


How to cite this URL:
Singh PP, Krishna A, Kumar O. Management of dyslipidemia in chronic kidney disease. J Indira Gandhi Inst Med Sci [serial online] 2021 [cited 2021 Dec 5 ];7:2-5
Available from: http://www.jigims.co.in/article.asp?issn=2394-9031;year=2021;volume=7;issue=1;spage=2;epage=5;aulast=Singh;type=0